HR
LOGC

Howe & Rusling’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Howe & Rusling’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150
Closed – – 1236
2022
Q2 		$0 Buy
+150
New +$76 ﹤0.01% 1200

Other funds holding LOGC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Howe & Rusling's LOGC Position: Q3 2022 in Review

Howe & Rusling sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2022, closing a stake of 150 shares.

Howe & Rusling first reported a position in LOGC in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 39 funds tracked by Wall St. Rank hold LOGC as of Q3 2022.

  • Howe & Rusling reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Howe & Rusling sold 150 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2022.
  • Howe & Rusling first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Howe & Rusling's LogicBio Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 39 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.